Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589910 | 0.95 | ADRB2 (0.80) | ADRB2 | |
| Trifluoroacetic Acid SCHEMBL3582661 | 0.95 | ADRB2 (0.77) | ADRB2 | |
| SCHEMBL3590466 | 0.90 | ADRB2 (0.82) | ADRB2 | |
| Trifluoroacetic Acid SCHEMBL3584806 | 0.90 | ADRB2 (0.77) | ADRB2 | |
| Trifluoroacetic Acid SCHEMBL3592687 | 0.89 | ADRB2 (0.91) | ADRB2 | |
| SCHEMBL3592488 | 0.88 | ADRB2 (0.81) | ADRB2 | |
| Bromide SCHEMBL3584497 | 0.88 | ADRB2 (0.80) | ADRB2 | |
| SCHEMBL3588405 | 0.87 | ADRB2 (0.64) | ADRB2 | |
| SCHEMBL3620941 | 0.87 | ADRB2 (0.79) | ADRB2 | |
| SCHEMBL4771293 | 0.86 | ADRB2 (0.66) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1915354-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | ADRB2 156/4885 |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | ADRB2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.